Arkolith/Insider Trading/XERS/Form 4

Persky Marla

DirectorXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Jun 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$91K
Net Open-Market Flow
-$91K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 4, 2026Grant(A)24K—$0151K
Jun 3, 2026Sell(S)16K$5.90$91K127K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 4, 2026Grant(A)33K$6.15$203K33K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001867096-26-000038) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Xeris Biopharma Holdings, Inc.

Build

Ask your agent about XERS insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001867096-26-000038"
Ask your agent
Use Arkolith to summarize insider buying and selling at Xeris Biopharma Holdings, Inc.
over the last 90 days and cite the filings.